Zoledronic acid Teva Generics Европейски съюз - български - EMA (European Medicines Agency)

zoledronic acid teva generics

teva generics b.v - монохидрат на золедроновата киселина - osteoporosis; osteitis deformans - бифосфонати - Лечение osteoporosisin стълб-menopausal жени за възрастни Менат повишен риск от фрактури, включително и с последните дъна-травми на бедрената кост . Лечение на остеопороза, свързан с дългосрочен системна глюкокортикоидной терапия след менопаузата жените за възрастни Менат повишен риск от фрактури. Лечение на болест на paget на костите при възрастни.

Zoledronic acid Teva Pharma Европейски съюз - български - EMA (European Medicines Agency)

zoledronic acid teva pharma

teva b.v. - золедронова киселина - osteoporosis; osteitis deformans; osteoporosis, postmenopausal - Лекарства за лечение на костни заболявания - treatment of osteoporosis: , in post-menopausal women;, in men; , at increased risk of fracture including those with a recent low-trauma hip fracture. treatment of osteoporosis associated with long-term systemic glucocorticoid therapy: , in post-menopausal women;, in men; , at increased risk of fracture. Лечение на болест на paget на костите при възрастни.

Comirnaty Европейски съюз - български - EMA (European Medicines Agency)

comirnaty

biontech manufacturing gmbh - single-stranded, 5’-capped messenger rna produced using a cell-free in vitro transcription from the corresponding dna templates, encoding the viral spike (s) protein of sars-cov-2 - covid-19 virus infection - Ваксини - comirnaty 30 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older.  comirnaty 30 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older.  comirnaty 10 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years.  comirnaty 3 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years.  comirnaty original/omicron ba. 1 (15/15 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older who have previously received at least a primary vaccination course against covid-19. comirnaty original/omicron ba. 4-5 (15/15 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older. comirnaty original/omicron ba. 4-5 (5/5 micrograms)/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty original/omicron ba. 4-5 (5/5 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years.  comirnaty original/omicron ba. 4-5 (1. 5/1. 5 micrograms)/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years.  comirnaty omicron xbb. 5 30 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older. comirnaty omicron xbb. 5 10 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty omicron xbb. 5 10 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty omicron xbb. 5 3 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years. Използването на тази ваксина трябва да бъде приложена в съответствие с официалните препоръки.

Antimyco-Acid Kupro 8g/100g+8g/100g cutaneous solution България - български - Изпълнителна агенция по лекарствата

antimyco-acid kupro 8g/100g+8g/100g cutaneous solution

Купро 94" ООД" - Други противогъбични лекарства за локално приложение - 8g/100g+8g/100g cutaneous solution

Antimyco-Acid Chemax Pharma  8 g/100 g + 8 g/100 g cutaneous solution България - български - Изпълнителна агенция по лекарствата

antimyco-acid chemax pharma  8 g/100 g + 8 g/100 g cutaneous solution

Химакс Фарма ЕООД - Комбинация - 8 g/100 g + 8 g/100 g cutaneous solution

Lanzacid 30 mg gastro - resistant capsules, hard България - български - Изпълнителна агенция по лекарствата

lanzacid 30 mg gastro - resistant capsules, hard

Чайкафарма Висококачествените Лекарства" АД" - Ланзопразол - 30 mg gastro - resistant capsules, hard

Klacid 125 mg/5 ml granules for oral suspension България - български - Изпълнителна агенция по лекарствата

klacid 125 mg/5 ml granules for oral suspension

bgp products limited - Кларитромицин - 125 mg/5 ml granules for oral suspension

Klacid 250 mg/5 ml granules for oral suspension България - български - Изпълнителна агенция по лекарствата

klacid 250 mg/5 ml granules for oral suspension

bgp products limited - 250 mg/5 ml granules for oral suspension

Klacid SR 250 mg film - coated tablets  България - български - Изпълнителна агенция по лекарствата

klacid sr 250 mg film - coated tablets 

bgp products limited - Кларитромицин - 250 mg film - coated tablets 

Klacid SR 500 mg powder for concetrate for solution for infusion България - български - Изпълнителна агенция по лекарствата

klacid sr 500 mg powder for concetrate for solution for infusion

bgp products limited - Кларитромицин - 500 mg powder for concetrate for solution for infusion